 | • レポートコード：MRC2303M069 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、113ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査資料によると、世界の神経内分泌腫瘍（NET）治療市場規模が、予測期間中（2023年〜2028年）に年平均成長率10%で拡大すると予測されています。本書は、神経内分泌腫瘍（NET）治療の世界市場にフォーカスし、最新動向と今後の市場性などをまとめており、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別（ソマトスタチンアナログ、標的療法、化学療法、その他）分析、疾患別（肺、膵臓、胃腸、その他）分析、エンドユーザー別（病院、診療所、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来の動向などが掲載されています。また、Boehringer Ingelheim International GmbH、Bristol-Myers Squibb、Eli Lilly & Company、F. Hoffmann-La Roche Ltd.、Ipsen、Novartis AG、Pfizer Inc.、Lantheus Holdings, Inc. (Progenics Pharmaceuticals)、Tarveda Therapeutics、AVEO Pharmaceuticals, Inc.、Hutchison MediPharma Limited、Jubilant Life Sciences Ltd.など、主要企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の神経内分泌腫瘍（NET）治療市場規模：製品別 - ソマトスタチンアナログにおける市場規模 - 標的療法における市場規模 - 化学療法における市場規模 - その他における市場規模 ・世界の神経内分泌腫瘍（NET）治療市場規模：疾患別 - 肺における市場規模 - 膵臓における市場規模 - 胃腸における市場規模 - その他における市場規模 ・世界の神経内分泌腫瘍（NET）治療市場規模：エンドユーザー別 - 病院における市場規模 - 診療所における市場規模 - その他における市場規模 ・世界の神経内分泌腫瘍（NET）治療市場規模：地域別 - 北米の神経内分泌腫瘍（NET）治療市場規模 アメリカの神経内分泌腫瘍（NET）治療市場規模 カナダの神経内分泌腫瘍（NET）治療市場規模 メキシコの神経内分泌腫瘍（NET）治療市場規模 … - ヨーロッパの神経内分泌腫瘍（NET）治療市場規模 イギリスの神経内分泌腫瘍（NET）治療市場規模 フランスの神経内分泌腫瘍（NET）治療市場規模 ドイツの神経内分泌腫瘍（NET）治療市場規模 … - アジア太平洋の神経内分泌腫瘍（NET）治療市場規模 中国の神経内分泌腫瘍（NET）治療市場規模 インドの神経内分泌腫瘍（NET）治療市場規模 日本の神経内分泌腫瘍（NET）治療市場規模 … - 南米/中東の神経内分泌腫瘍（NET）治療市場規模 ブラジルの神経内分泌腫瘍（NET）治療市場規模 アルゼンチンの神経内分泌腫瘍（NET）治療市場規模 南アフリカの神経内分泌腫瘍（NET）治療市場規模 … - その他地域の神経内分泌腫瘍（NET）治療市場規模 ・競争状況 ・市場機会・将来の動向 |
The Neuroendocrine Tumor Treatment Market is projected to register a CAGR of 10% during the forecast period (2023 – 2028).
The ongoing outbreak of COVID-19 showed an impact on the Neuroendocrine Tumor Treatment market because hospital and healthcare services were significantly reduced due to social distancing measures taken by governments across the globe. Moreover, the COVID-19 pandemic not only affected the global economy but also showed a huge impact on the functioning of general hospital care for non-COVID-19 patients in hospitals across the globe. An article titled “Impact of the COVID-19 pandemic on neuroendocrine tumour services in England” published in the journal of Endocrine in January 2021 indicated that during the COVID-19 pandemic, there were particular concerns regarding the specialist tumor treatment services. The article stated that the major disruption in specialist neuroendocrine treatment services included relevantly increased waiting times for both new and follow-up appointments, with an especially substantial delay of follow-up appointments. The lag in other treatment services during the COVID-19 pandemic greatly impacted the neuroendocrine tumor treatment market.
The neuroendocrine tumor treatment market is driven by the factors such as the growing prevalence of neuroendocrine cancer, technological advancements in the field of neuroendocrine tumor treatment, and the rise in the number of government initiatives. An article titled “Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)” published in the Journal of Cancers in April 2022 indicated the occurrence of neuroendocrine have been largely increasing in the past three to four decades. Also, there has been an increase in the innovations in the treatment methods for neuroendocrine treatment including somatostatin analogs, INF α, Radionuclide Treatment, Transarterial treatment, Targeted therapy, immunotherapy, CAR-T-Cell therapy, bispecific antibodies, vaccines, Cytotoxic Chemotherapy of Highly Differentiated and Low Differentiated G1 and G2 GEP NETs. The rising number of innovative treatments for the neuroendocrine tumor in the recent years have significantly improved the growth of the neuroendocrine tumor treatment in recent years.
The Department of Health of Commonwealth of Australia in January 2022 released a grant of USD 63.4 million for the rare cancers and rare diseases research under the 2021 Rare Cancers, Rare Diseases and Unmet Need (RCRDUN) grant opportunity. Specifically, the Flinders University received a funding of USD 2,374,220.10 for the project “Implementing a Nurse-Enabled, Shared-Care Model to Address Unmet Needs of People with Neuroendocrine Tumours: the AUS-NET Trial”. The investments in the rare cancer treatment studies are a part of the long-term national health plan of the Australian government. Such investments by various government organizations are likely to add to the growth of the neuroendocrine tumor treatment market in the forecast period.
However, the high cost of neuroendocrine tumor treatment methods along with the lack of awareness among people are hindering the growth of the studied market.
Neuroendocrine Tumor Treatment Market Trends
The Somatostatin Analogs (SSAs) Segment is Expected to Hold a Major Market Share in the Neuroendocrine Tumor Treatment Market.
The Somatostatin Analogs (SSAs) hold the major segment in the Neuroendocrine Tumor Treatment market. The Somatostatin Analogs (SSAs) are found to be the widely drugs used for the treatment of neuroendocrine carcinoma as they control cancer growth, symptoms, and target biomarkers. They are accounted for the largest revenue share owing to safe treatment procedure offered by SSAs.
SSAs are found to be generally used to treat patients who are resistant to radiation therapy and surgery. Many SSAs are thus currently under clinical trial phase and waiting for approval, hence the market is expected to witness high growth over the forecast period. An article titled “Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors” published in the Journal of Oncology in January 2022 discussed the action of two somatostatin analogs, in the treatment of neuroendocrine tumors. The article indicated that the somatostatin analogs were one of the most preferred treatment methods for neuroendocrine tumors. The rising prevalence of use of somatostatin analogs for neuroendocrine tumor treatment are adding to the growth of the studied market.
Another article presented in the journal of Patient-Reported Outcomes in September 2021 titled “Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors” performed a qualitative survey that studied the patient experiences with somatostain analog therapy. The study indicated that satisfaction with Long Acting SSA injection is high among patients in the treatment. Such advantages of the somatostatin analogs are expected to add to the grwoth of the market in the forecast period.
Several key market players have been focusing on the researcvh and development of somatostatin amalogs for neuroendocrine tumor treatment. In March 2022, Amyrt Pharma plc reported that the successful bioavailability study for Mycapssa (octreotide capsules) in a planned Phase 3 study in the treatment of carcinoid symptoms associated with Neuroendocrine Tumors (NET). The study demonstrated that doses of Mycapssa up to 80mg resulted in the desired bioavailability and dose proportionality with an acceptable safety and tolerability profile. The rise in the research and development of such somatostatin analogs for the treatment of neuroendocrine tumor are adding to the growth of the studied segment in the forecast period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period (2022 – 2027).
The rise in the adoption of highly advanced techniques and systems in the neuroendocrine tumor treatment field and the technological advancements made in cancer therapeutics is expected to boost the growth of the market in the North American region. The high awareness among the population on the availability of innovative therapeutics in neuroendocrine tumor treatment in the market contributes to the high market growth in the region.
The rising number of neuroendocrine cancer cases in the North American region is adding to the growth of the neuroendocrine tumor treatment market. According to the American Society of Clinical Oncology Neuroendocrine Tumor Statistics updated in February 2022, more than 12,000 people in the United States are diagnosed with a Neuroendocrine Tumor each year, and approximately 175,000 people are living with the diagnosis. The article also stated that the number of cases has been in the rise in recent years.
According to the National Center for Advancing Translational Sciences – Genetic and Rare Diseases Information Center data updated in November 2021, there were around 3,000 to 30,000 people in the United States affected by carcinoid tumor, which usually develops in the gastrointestinal tract or the lungs. The wide prevalence of the neuroendocrine cancer cases in the region is expected to add to the market growth.
The recent approval of neuroendocrine tumor treatment drugs by the Food and Drug Administration in the United States region is adding to the growth of the studied market in the forecast period. For instance, in August 2021, the United States Food and Drug Administration approved belzutifan (Welireg), a hypoxia-inducible factor inhibitor for adult patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery. The rise in the approval of such drugs is adding to the growth of the neuroendocrine treatment market in the United States region in the forecast period. There are also supportive insurance policies in this region facilitating neuroendocrine treatment, such as Medicare, Medicaid, and Tricare that helps in driving the overall growth of the market.
Thus the increasing necessity for Neuroendocrine Tumor Treatment technology coupled with increasing investment in the health care department is known to propel the growth of the market in this region.
Neuroendocrine Tumor Treatment Market Competitor Analysis
The key players are found undertaking strategies such as product launches, regional expansion, partnership and distribution agreements, to strengthen their market position. There are also various companies that are found focusing on organic growth strategies product approvals and others such as patents and events. The inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. Some of the companies which are currently dominating the market are Pfizer Inc., Novartis AG, Ipsen, Boehringer Ingelheim International GmbH, Eli Lilly & Company, among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 MARKET DYNAMICS
3.1 Market Overview
3.2 Market Drivers
3.2.1 Increasing Prevalence of Neuroendocrine Carcinoma
3.2.2 Technological Advancements
3.2.3 Rising Number of Government Initiatives
3.3 Market Restraints
3.3.1 High Cost of Development
3.3.2 Lack of Awareness Among People
3.4 Porter’s Five Force Analysis
3.4.1 Threat of New Entrants
3.4.2 Bargaining Power of Buyers/Consumers
3.4.3 Bargaining Power of Suppliers
3.4.4 Threat of Substitute Products
3.4.5 Intensity of Competitive Rivalry
4 EXECUTIVE SUMMARY
5 MARKET SEGMENTATION
5.1 By Products
5.1.1 Somatostatin Analogs (SSAs)
5.1.2 Targeted Therapy
5.1.3 Chemotherapy
5.1.4 Others
5.2 By Indication
5.2.1 Lungs
5.2.2 Pancreas
5.2.3 Gastrointestinal
5.2.4 Others
5.3 By End User
5.3.1 Hospitals
5.3.2 Clinics
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Boehringer Ingelheim International GmbH
6.1.2 Bristol-Myers Squibb
6.1.3 Eli Lilly & Company
6.1.4 F. Hoffmann-La Roche Ltd.
6.1.5 Ipsen
6.1.6 Novartis AG
6.1.7 Pfizer Inc.
6.1.8 Lantheus Holdings, Inc. (Progenics Pharmaceuticals)
6.1.9 Tarveda Therapeutics
6.1.10 AVEO Pharmaceuticals, Inc.
6.1.11 Hutchison MediPharma Limited
6.1.12 Jubilant Life Sciences Ltd.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS